Annalisa Morgan
Clinical FellowAbout
Titles
Clinical Fellow
Biography
Annalisa Morgan, MD is a neurologist specializing in inflammatory disorders of the central nervous system, including multiple sclerosis (MS), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neuromyelitis optic spectrum disorder (NMOSD), and autoimmune encephalitides. She is currently an assistant professor of neurology at Yale School of Medicine.
Dr. Morgan received her medical degree from Rush Medical College and completed her neurology residency at the Cleveland Clinic, where she also served as chief resident. She then went on to complete fellowship training in neuroimmunology at Yale. Her clinical approach is rooted in building long-term, meaningful relationships with her patients and keeping pace with the rapidly evolving science in the field.
In addition to patient care, Dr. Morgan is actively involved in research, with a primary focus on clinical trials investigating novel therapies and strategies to improve current treatment approaches in neuroimmunology.
Appointments
Neurology
Clinical FellowPrimary
Other Departments & Organizations
Education & Training
- Neuroimmunology Fellowship
- Yale
- Neurology Residency
- Cleveland Clinic
- MD
- Rush Medical College
- BS
- University of Michigan, Neuroscience
Board Certifications
Neurology
- Certification Organization
- AB of Psychiatry & Neurology
- Original Certification Date
- 2023
Research
Publications
2024
Iatrogenic Epileptogenicity Caused by CNS Drugs: A Short Case Series and Narrative Review.
Morgan A, Punia V. Iatrogenic Epileptogenicity Caused by CNS Drugs: A Short Case Series and Narrative Review. Neurohospitalist 2024, 14: 291-295. PMID: 38895019, DOI: 10.1177/19418744241239382.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsParaneoplastic Immune Mediated
Morgan A, Kunchok A. Paraneoplastic Immune Mediated. In: Aminoff M, Pomeroy S, eds. The Netter Collection of Medical Illustrations: Nervous System, Volume 7, Part I- Brain. 3rd edition. Elsevier. 2024: 10.19-10.20.ChaptersOther Neuroimmunologic Syndromes
Morgan A, Abbatemarco J. Other Neuroimmunologic Syndromes. In: Aminoff M, Pomeroy S, eds. The Netter Collection of Medical Illustrations: Nervous System, Volume 7, Part I- Brain. 3rd edition. Elsevier. 2024: 10.17.ChaptersStiff-Man Syndrome
Morgan A, Abbatemarco J. Stiff-Man Syndrome. In: Aminoff M, Pomeroy S, eds. The Netter Collection of Medical Illustrations: Nervous System, Volume 7, Part I- Brain. 3rd edition. Elsevier. 2024: 10.18.ChaptersLongitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis
Morgan A, Li Y, Thompson NR, Milinovich A, Abbatemarco JR, Cohen JA, Ontaneda D, Punia V, Rae-Grant A, Galioto R, Kunchok A. Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis. Neurology. 2024 Feb 27;102(4):e208019. doi: 10.1212/WNL.0000000000208019. Epub 2024 Jan 24. PMID: 38266213.Peer-Reviewed Original ResearchManagement Approaches in Radiographically Isolated Syndrome
Morgan A, Longbrake E. Management approaches in radiographically isolated syndrome. Practical Neurology (US). 2024;23(1):39-42.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2023
The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis.
Morgan A, Tallantyre E, Ontaneda D. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis. Expert Rev Neurother 2023, 23: 433-444. PMID: 37129299, DOI: 10.1080/14737175.2023.2208347.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements